Steegmann J L, Requena M J, García-Buey M L, Granados E, Romero R, Fernández-Rañada J M, Moreno R
Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain.
Am J Hematol. 1998 Sep;59(1):95-7. doi: 10.1002/(sici)1096-8652(199809)59:1<95::aid-ajh19>3.0.co;2-0.
A patient with chronic myeloid leukemia (CML) treated with interferon alpha (IFN alpha) and who developed autoimmune hepatitis (AIH) is described. The patient was treated with IFN alpha 2a, a complete cytogenetic response was achieved 5 months later, and this response has lasted now more than 7 years. Autoimmune hypothyroidism appeared at 18 months of treatment, and 1 year later severe type I autoimmune hepatitis developed. To our knowledge this is the first report of such complication in an IFN alpha-treated CML patient.
本文描述了一名接受α干扰素（IFNα）治疗的慢性髓性白血病（CML）患者，该患者发生了自身免疫性肝炎（AIH）。该患者接受了IFNα 2a治疗，5个月后实现了完全细胞遗传学缓解，且这种缓解持续至今已超过7年。治疗18个月时出现自身免疫性甲状腺功能减退，1年后发生严重的I型自身免疫性肝炎。据我们所知，这是IFNα治疗的CML患者出现此类并发症的首例报告。
